Key Highlights

  • Loss per share was USD 0.18 against an estimate of a USD 0.13 loss.
  • Revenue was USD 47,628 against an estimate of USD 2.04 million.
  • Net loss was USD 3.16 million, compared with USD 3.56 million.
  • Cash and cash equivalents were USD 11.53 million at September 30, 2026.

Daré Bioscience (NASDAQ:DARE) reported Revenue of USD 47,628 for the third quarter of 2026, compared with USD 2,262 in the prior-year quarter, against an estimate of USD 2.04 million. Basic and diluted loss per common share was USD 0.18, compared with USD 0.28, against an estimate of a USD 0.13 loss.

Net loss was USD 3.16 million, compared with USD 3.56 million. Revenue consisted of Research and Development services and other revenue.

Third Quarter Results

Cost of revenues was USD 180,479, with none reported in the prior-year quarter. Selling, general and administrative expenses were USD 2.64 million, compared with USD 2.50 million, and research and development expenses were USD 318,906, compared with USD 1.18 million. Total operating expenses were USD 2.96 million, compared with USD 3.67 million.

The loss from operations was USD 3.09 million, compared with USD 3.67 million. Other expense was USD 65,791, compared with other income of USD 109,382. Weighted average shares outstanding, basic and diluted, were 17,421,580, compared with 12,755,112. The comprehensive loss was USD 3.15 million, including a foreign currency translation adjustment of USD 6,586.

Nine-Month Results

For the nine months ended September 30, 2026, revenue was USD 387,629, compared with USD 6,517, and cost of revenues was USD 742,693. Selling, general and administrative expenses were USD 7.48 million, compared with USD 7.19 million, and research and development expenses were USD 1.22 million, compared with USD 4.90 million.

Total operating expenses for the nine months were USD 8.70 million, compared with USD 12.09 million, and the loss from operations was USD 9.06 million, compared with USD 12.08 million. The net loss was USD 9.14 million, compared with USD 11.96 million, and loss per share was USD 0.59, compared with USD 1.18. Weighted average shares outstanding for the nine months were 15,622,034, compared with 10,143,078.

Balance Sheet and Going Concern Disclosure

Cash and cash equivalents were USD 11.53 million at September 30, 2026, compared with USD 24.71 million at December 31, 2025. The filing states that a majority of the cash represented grant funds received under grant agreements with a private foundation, which may be applied solely toward direct costs of the funded projects, subject to an indirect cost allowance.

Total Assets were USD 22.10 million, compared with USD 32.47 million, and total current liabilities were USD 13.71 million, compared with USD 23.69 million. Total liabilities were USD 19.76 million, compared with USD 29.63 million, and included a Liability related to the sale of future royalties. Additional paid-in Capital was USD 200.54 million, compared with USD 191.95 million. The filing discloses substantial doubt about the company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.

Daré Bioscience Q3 2026 Earnings: Key Takeaways

Daré Bioscience reported third quarter 2026 revenue of USD 47,628, a net loss of USD 3.16 million and a loss per share of USD 0.18. Cash and cash equivalents were USD 11.53 million at September 30, 2026.